Core Viewpoint - Smoore International (06969.HK) experienced a significant stock price increase of 10.18%, closing at HKD 17.32 per share, marking a new high since September 2022 and breaking a two-year stagnation period [2]. Company Performance - For 2024, Smoore International is projected to achieve total revenue of approximately RMB 11.799 billion, reflecting a year-on-year growth of about 5.3%. The group's gross profit is expected to be around RMB 4.412 billion, with a gross margin of 37.4%, and a net profit of approximately RMB 1.303 billion. The board has also proposed a final dividend of HKD 0.05 per share [5]. Market Dynamics - The tightening regulations on illegal vaping products in the U.S. are seen as beneficial for compliant brands, with Smoore International positioned to gain from this trend as a leading electronic cigarette manufacturer [3][4]. - Other Hong Kong stocks in the electronic cigarette sector, such as Huabao International (00336.HK) and China Tobacco Hong Kong (06055.HK), also showed positive movements, indicating a broader market interest [3]. Analyst Ratings - First Shanghai Securities has issued a "Buy" rating for Smoore International with a target price of HKD 19, suggesting potential upside from the current stock price. The company is expected to benefit from its exclusive supply of heated not-burn (HNB) products to British American Tobacco, with significant profit growth anticipated starting in the second half of the year [6]. - Guojin Securities also highlighted the positive outlook for the HNB industry, indicating that Smoore International is well-positioned for growth due to its strategic partnerships and market expansion plans [6].

Summary of Smoore International and the New Tobacco Industry Update Company and Industry Overview - The report focuses on Smoore International and the new tobacco industry, particularly the electronic cigarette and cannabis vaporizer markets [1][4]. Key Points and Arguments - **Stock Price Movement**: Smoore International's stock price has increased due to two main factors: the upcoming launch of British American Tobacco's (BAT) second-generation product Hilo in Japan and the diminishing impact of equivalent tariffs on exports. The company primarily exports electronic cigarettes and cannabis vaporizers from Southeast Asia, where a 10% basic tariff exemption exists, mostly borne by customers [2][4]. - **Stable Business Performance**: Smoore's electronic cigarette and cannabis vaporizer businesses are performing steadily. The company plans to shift domestic production of cannabis vaporizers to overseas bases to further mitigate tariff impacts, indicating resilience and optimistic future prospects [1][4]. - **Growth Opportunities from Hilo**: BAT's Hilo product, expected to launch in mid-2025, presents new growth opportunities for Smoore. The long-term market potential is significant, with the HMT (new heating not burning technology) segment showing good growth prospects, primarily attracting traditional cigarette users [5][6]. - **Focus on Electronic Cigarettes and New Ventures**: Smoore will continue to focus on electronic cigarettes and related fields while actively expanding its own brands and medical-related businesses. The regulatory environment is improving, benefiting larger companies through industry consolidation and standardization [1][6]. - **Product Improvements with Glo Halo**: The new Glo Halo product has reduced heating time from 15 seconds to 5 seconds, enhancing user experience and competitiveness. This product is expected to increase market penetration [1][8]. Additional Important Insights - **Technological Advancements**: Glo Halo employs a new needle heating technology that improves heating uniformity, reduces burnt taste, and extends device lifespan while maintaining flavor quality [3][10]. - **Market Dynamics in Japan**: Japan has the highest penetration rate for HNB products globally, nearing 50%. The well-established consumer education and distribution channels make it a critical market for validating HNB product performance [12][13]. - **Pricing Strategy**: Smoore's pricing strategy for Glo Halo aims to compete directly with IQOS, positioning itself in the high-end market with retail prices around 580 yen, similar to IQOS's mainstream products [14][15]. - **Competitive Landscape**: In the U.S. market, PMI is leading the promotion of its IQOS products, with expectations of capturing 10% of the cigarette and HNB market share by 2030. Smoore's entry into high-value segments through equipment supply and technology development is noteworthy [16][17][18]. - **Management Confidence and Market Potential**: The management team shows strong confidence in the company's future, with significant market potential if sales targets are met, indicating substantial investment opportunities [7][6].

思摩尔国际(06969.HK)涨超7%，盘中股价一度触及17港元，创2022年8月以来新高。 ...

港股消费ETF（159735）跟踪中证港股通消费主题指数，该指数选取港股通范围内流动性较好、市值较 大的50只消费主题相关股票组成指数样本，采用自由流通市值加权，以反映港股通内消费类股票的整体 表现。 财信证券指出，整体而言，今年"五一"假期旅游市场呈现全面复苏态势，我们认为主要受益于三大核心 驱动因素：一是"请4休11"拼假模式有效激活长线旅游需求；二是免签及离境退税等出入境便利化政策 持续释放红利；三是多元化文旅消费场景创新显著提升市场吸引力。在此带动下，居民出行半径显著扩 大，消费意愿持续提升。展望后市，随着扩内需政策持续加码，叠加消费信心逐步修复，旅游行业有望 延续复苏态势。 5月14日早盘，港股集体上涨，截至发稿，中证港股通消费主题指数涨1.08%。 相关ETF方面，截至发稿，港股消费ETF（159735）涨0.73%，换手率超1.88%。成分股中，思摩尔国 际涨超5%，零跑汽车涨超4%，万洲国际、波司登、美团-W等多股跟涨。 消息面来看，据经济参考报，多个部门近期强调促进商旅文体健多业态消费融合、各地拿出真金白银促 进融合新业态发展、企业商圈计划引入更多文化体育要素。记者关注到，多元业态融合创新正 ...

Group 1 - The stock of Smoore International (06969.HK) surged in the afternoon, currently up by 9.7% [1]

Group 1 - The core point of the article is that Smoore International experienced a significant short-term price increase, rising nearly 12% to HKD 15.9 [1]

Core Viewpoint - The strong performance of Philip Morris International's (PMI) Q1 2025 results indicates significant growth potential for the heated tobacco product (HNB) market, which is relevant for Smoore International as a key supplier in this sector [1][2] Group 1: Company Performance - Smoore International's stock rose over 3%, currently trading at 13 HKD with a transaction volume of 73.1681 million HKD [1] - PMI's Smoke-Free Products (SFP) revenue increased by 20.4% year-on-year, with gross profit rising by 33.1% and a gross margin exceeding 70%, up by 6.7 percentage points [1] - The shipment volume for PMI's products grew by 14.4% year-on-year, with HNB, oral tobacco, and e-cigarettes increasing by 12%, 27%, and 107% respectively [1] Group 2: Market Insights - The international tobacco giants are advancing their smoke-free strategies, with PMI's Q1 performance aligning with expectations for HNB growth, particularly in the U.S. market [2] - The HNB market has substantial growth potential, with regulatory advantages over vaping products, including lower appeal to youth and easier harm reduction validation [2] - The competitive landscape for HNB is favorable due to fewer participating manufacturers, and British American Tobacco's new Glo Hilo product shows significant improvements in performance and user experience compared to both leading products and previous generations [2]

Investment Rating - The investment rating for the company is "Buy" [4] Core Insights - The report highlights the strong performance of Philip Morris International's (PMI) Smoke-Free Products (SFP) in Q1 2025, with a revenue increase of 20.4% year-on-year and a gross profit increase of 33.1%, resulting in a gross margin exceeding 70% [1][3] - The report emphasizes the growth potential of the Heat-Not-Burn (HNB) market, particularly in the U.S. where trials have shown strong market feedback, and the company expects double-digit growth for IQOS sales throughout the year [2][3] - The new nicotine pouch ZYN has shown impressive growth, with a 53% increase in shipments in the U.S. and similar growth internationally, indicating a robust demand for innovative tobacco products [2][3] Summary by Sections Company Performance - PMI's HNB products, including IQOS, have captured over 70% market share, with a shipment increase of 12% for HNB products in Q1 2025 [1][2] - The gross margin for IQOS has improved significantly due to scale efficiencies and productivity enhancements [1] Market Trends - The HNB penetration rate in Japan continues to rise, reaching 47.8% in March 2025, indicating ongoing market growth even in mature markets [1][2] - The U.S. HNB market is poised for expansion, with ongoing trials expected to lead to broader market entry [2] Financial Projections - The company is projected to achieve revenues of HK$128.9 billion, HK$151.1 billion, and HK$173.5 billion for the years 2025 to 2027, with year-on-year growth rates of 9%, 17%, and 15% respectively [3][9] - Net profit forecasts for the same period are HK$13.2 billion, HK$19.2 billion, and HK$24.8 billion, reflecting growth rates of 2%, 45%, and 29% [3][9]

Financial Performance - Total revenue for 2024 was RMB 11,798.662 million, representing a 5.3% increase from RMB 11,203.250 million in 2023[10] - Gross profit for 2024 was RMB 4,411.969 million, with a gross margin of 37.4%, down from 38.7% in 2023[10] - Net profit for 2024 decreased to RMB 1,303.255 million, reflecting a net profit margin of 11.0%, compared to 14.7% in 2023[10] - The company achieved revenue of approximately RMB 11,798.66 million in the review period, representing a year-on-year growth of about 5.3%[27] - The group's total revenue for the year ended December 31, 2024, was approximately RMB 11,798,662 thousand, representing a 5.3% increase from RMB 11,203,250 thousand in 2023[72] - The gross profit for the review period was approximately RMB 4,411,969 thousand, a 1.6% increase from RMB 4,340,911 thousand in 2023, with a gross margin decrease from 38.7% to 37.4%[73] Asset Management - The company reported a significant increase in non-current assets, reaching RMB 10,807.950 million in 2024, up from RMB 5,937.532 million in 2023[10] - Current assets decreased to RMB 16,846.428 million in 2024 from RMB 19,570.752 million in 2023, while current liabilities increased to RMB 5,259.365 million[10] - The asset-liability ratio increased to 20.8% in 2024 from 16.1% in 2023, indicating a higher proportion of liabilities relative to total assets[12] - As of December 31, 2024, the group's current assets net value was approximately RMB 11,587,063 thousand, down from RMB 16,004,419 thousand in 2023[86] - The group's current ratio as of December 31, 2024, was approximately 320.3%, a decrease from 548.8% in 2023[87] - The asset-liability ratio as of December 31, 2024, was approximately 26.2%, compared to 19.1% in 2023[90] Dividend and Shareholder Information - The company plans to declare a final dividend of HKD 0.05 per ordinary share for the year ended December 31, 2024[11] - The board has proposed a final dividend of HKD 0.05 per ordinary share for the year ending December 31, 2024, subject to approval at the upcoming annual general meeting[166] - The company's distributable reserves as of December 31, 2024, amount to RMB 7,047.7 million[161] Business Segments and Growth - The electronic vaporization segment showed positive growth due to increased regulatory enforcement against non-compliant products, leading to a shift in consumer demand towards compliant products[14] - The company successfully launched new business lines in heated non-combustible products and aerosol medical and beauty products, contributing to overall business diversification[14] - In the heating non-combustion product sector, the company plans to support strategic clients in launching products in more markets, focusing on user feedback for continuous product iteration[20] - The company successfully launched the "Lan Zhi" brand in the aerosol beauty business, which has gained recognition through online promotions and offline channels, achieving impressive sales during major marketing events[16] - The company anticipates that 2025 will be a critical year for the second growth curve, with plans to expand into harm reduction products and strengthen its competitive edge in core businesses[21] - The group launched multiple new product series in overseas markets across various segments, including electronic vaporization and medical vaporization, enhancing R&D efficiency through scientific classification management[29] Research and Development - The company is committed to increasing R&D investment, particularly in aerosol medical and heating non-combustible products, which have shown satisfactory breakthroughs during the review period[16] - Research and development expenditure for the period was approximately RMB 1,572,313 thousand, an increase of 6.0% year-on-year, accounting for about 13.3% of total revenue[48] - R&D expenditure for electronic nicotine delivery systems was RMB 1,034,668 thousand, accounting for 65.8% of total R&D spending, with a slight increase of 0.1% year-on-year[52] - R&D expenditure for medical and beauty aerosol products increased by 41.3% year-on-year to RMB 392,180 thousand, accounting for 24.9% of total R&D spending[52] - The company filed a total of 1,558 new patent applications globally during the period, including 893 invention patents, bringing the cumulative total to 9,253 patents[51] Market and Regulatory Environment - The group achieved a revenue contribution of approximately 37.4% from the U.S. market during the review period, with significant legal and regulatory developments impacting the electronic nicotine delivery systems (ENDS) products[33] - The FDA has taken action on over 99% of PMTA submissions, with ongoing legal challenges affecting several ENDS products[33] - The UK has not introduced any significant laws or regulations related to electronic cigarettes and vaping devices as of December 31, 2024, contributing 25.5% to revenue[34] - In the EU, countries with flavor restrictions include Finland, Estonia, Hungary, and others, with a revenue contribution of 7.9%[34] - Hong Kong has proposed a complete ban on alternative smoking products, which is expected to impact 32.8% of revenue by December 31, 2024[36] - The mainland China market's revenue contribution is approximately 2.2%, with new regulations being implemented in July-August 2024[36] Corporate Governance - The board consists of eight directors, including three independent non-executive directors, ensuring sufficient checks and balances within the board[109] - The company has adopted the corporate governance code and complied with all provisions except for the separation of the roles of chairman and CEO, which are held by the same individual[108] - The independent non-executive directors reviewed and confirmed that the related party transactions were conducted on fair and reasonable terms[105] - The company has established a clear process for the appointment and re-election of directors, with terms set at three years[115] - The company has implemented an anti-corruption policy to prevent bribery and corruption within its operations[130] Employee and Gender Diversity - Overall employee gender ratio is 48.14% female (8,939) and 51.86% male (9,631) across the company[124] - The company has appointed one female executive director and one female non-executive director as of December 31, 2024[122] - The board consists of 25% female members (2 out of 8) and 75% male members (6 out of 8) as of December 31, 2024[124] - The company emphasizes gender diversity in recruitment and selection processes at all levels[122] Risk Management - The company’s risk management and internal control systems aim to manage operational efficiency and ensure compliance with relevant laws and regulations[142] - The Board has confirmed the effectiveness of the risk management and internal control systems as of December 31, 2024[144] - The company's overall risk management process is integrated into daily operations, with management responsible for identifying and responding to risks[144] Stock Options and Incentives - The company has granted a total of 129,524,700 stock options, with 98,158,700 options currently exercisable[193] - The share incentive plan aims to recognize and reward contributions from eligible participants to the group's growth and development, while also attracting suitable personnel[195] - The maximum number of shares that can be held under the plan at any time is capped at 2% of the total issued shares (excluding treasury shares)[198] - The total number of shares issued to each eligible participant under the plan within any 12-month period cannot exceed 1% of the total issued shares (excluding treasury shares)[200]

Summary of Smoore International Conference Call Company Overview - **Company**: Smoore International - **Fiscal Year**: 2024 - **Revenue**: 11.8 billion CNY, a year-on-year increase of 5.3% [3] - **Gross Margin**: 37.4%, down from 38.7% in 2023 [3] Key Points Financial Performance - **Gross Margin Decline**: Slight decrease attributed to rapid growth in low-margin ODM business, while self-branded business share is expected to support future margin growth [2][3] - **Sales Expenses**: Increased significantly to 919 million CNY, primarily for overseas channels and beauty business expansion in China [2][3] - **Net Profit**: Pre-tax profit decreased by 14.5% to 1.65 billion CNY due to increased sales and tax expenses [3] Market Dynamics - **European Market**: Ban on disposable e-cigarettes in several countries is expected to drive the development of refillable products [4] - **US Market**: Stable performance of closed products, but a 2.4% year-on-year decline due to customer payment capacity issues [4] - **Chinese Market**: Low base but a 25% year-on-year growth, with limited short-term expectations [4] Business Developments - **Collaboration in Medical Field**: Progress in nebulized medical devices for pulmonary hypertension treatment, with self-developed drug combination products expected to launch by late 2020 or early 2021 [5] - **ECS Business Growth**: Anticipated significant development phase in ECS (Electronic Cigarette Supply Chain) by 2025, with increasing revenue and profit contributions [6] Regulatory Environment - **US FDA Regulations**: Strict regulations impacting HNB (Heated Not Burned) market; first-generation products approved, while others require PMTA approval [12] - **Compliance Opportunities**: Stricter enforcement against non-compliant products in the US provides opportunities for compliant customers [19] Strategic Responses - **Differentiation Strategy**: To counteract profit pressure from the trend towards larger pod products, Smoore is launching innovative products in the US and Europe and empowering local distributors [8] - **Investment in Low-Risk Assets**: Growth in non-current assets due to increased fixed assets and adjustments in financial product allocations [10] Future Outlook - **2025 Revenue Growth**: Expected high single-digit growth driven by HNB products entering more markets and continued growth in self-branded and ODM businesses [23][24] - **Profitability Expectations**: Anticipated stable profit margins despite increased R&D investments and long-term incentive plan amortization [26] Additional Insights - **Market Share Gains**: Smoore's self-branded products have outpaced industry growth due to increased market share and technological advantages [9] - **Impact of Tariffs**: The 35% tariff on Chinese products has a minimal impact due to preemptive establishment of Southeast Asian production bases [30] This summary encapsulates the key insights from the conference call, highlighting Smoore International's financial performance, market dynamics, strategic initiatives, and future outlook.